JonesResearch downgraded Decibel Therapeutics (DBTX) to Hold from Buy after Decibel agreed to be acquired by Regeneron (REGN) for $4.00 per share along with a non-tradeable contingent value right, or CVR, to receive up to $3.50 per share in cash subsequent achievement of certain milestones related to DB-OTO.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on DBTX: